* Vyne Therapeutics Inc is expected to show a rise in quarterly revenue when it reports results on May 9 (estimated) for the period ending January 1 0001
* The Bridgewater New Jersey-based company is expected to report a 1.0% increase in revenue to $100 thousand from $99 thousand a year ago, according to the estimate from one analyst, based on LSEG data.
* LSEG's mean analyst estimate for Vyne Therapeutics Inc is for a loss of 24 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Vyne Therapeutics Inc is $5.75, above its last closing price of $2.71.
This summary was machine generated May 7 at 11:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments